CyberKnife Center of Miami Seeks Patients for Prostate Cancer Trial
Posted on: Tuesday, 4 October 2005, 15:00 CDT
The CyberKnife Center of Miami recently announced plans for a prostate cancer trial this year, and the center is seeking 20 patients to participate in the trial. Using a robotic arm and missile guidance technology, CyberKnife delivers targeted doses of radiation to often inoperable tumors with sub-millimeter accuracy. Until recently, CyberKnife technology was used secondarily to augment traditional radiation treatment of prostate cancer. The Miami trial will help determine if CyberKnife treatments could be primary, saving patients' time and money.
Using image-guided radiosurgery, CyberKnife can accurately target and deliver maximum radiation doses needed to attack the cancer and not damage healthy tissue. By limiting irradiation to normal tissue, the CyberKnife is able to deliver a higher and more effective dose. Shaping the treatment to the patient's anatomy is one of the great advantages of image-guided technology, such as the CyberKnife. The center treats tumors and cancer in the brain, head and neck, spine, lungs, liver, breast and pancreas. Treatment is covered by major insurance carriers and costs 20 to 45 percent less than conventional surgery.
"Typically prostate cancer patients can receive up to 37 daily treatments of radiation within a two-month period," said Dr. James Schwade, the executive director of the CyberKnife Center of Miami who will oversee the trial. "Earlier trials have shown that CyberKnife can be as effective with as few as five treatments in a one week period. We hope to back those assertions up and help make CyberKnife procedures a primary treatment for prostate cancer."
Patients who meet the following criteria are eligible and are encouraged to contact the CyberKnife Center of Miami for more information. 1) Told by their physician that they have prostate cancer. 2) Have had a biopsy, and the pathology reports states a Gleason scale that is less than or equal to 7. 3) Have PSA level of 10 or lower. 4) Have not previously received radiation treatments to the pelvis area. 5) Ultrasound shows the prostate gland volume to be 80 cc or less. 6) Have not been diagnosed with any other type of cancer in the last year. 7) Have satisfactory kidney function. 8) Have not had a prostate surgical procedure, such as Transurethal Resection of the Prostate (TURP).
Patients who would like more information or have questions about eligibility should call (800) 204-0455 or visit http://www.cyberknifemiami.com.
More than 10,000 patients worldwide have been treated by the CyberKnife stereotactic radiosurgery system at centers worldwide. Developed by Dr. John Adler, a Stanford University neurosurgeon, it is the only robotic image-guided radiation system that enables the precise targeting and treatment of tumors throughout the body. The CyberKnife Center of Miami is an independent, free-standing center and is open to select community physicians who have been trained and credentialed in CyberKnife radiosurgery. For more information, call 800-204-0455 or visit http://www.cyberknifemiami.com.
Source: Business Wire
Related Articles
- Thompson Cancer Survival Center to Take Cancer Program to the Next Level With Purchase of Elekta Infinity Treatment System
- Skagit Valley Hospital Regional Cancer Care Center Enhances Patient Care With Elekta Axesse(TM)
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
- Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer
- PHT LogPad Enables Temple University to Examine Clinical Benefit of a Medical Call Center Upon Patients With COPD; Novel Trial Aims to Reduce COPD-Related Deaths and Hospitalizations, Improve Quality of Life, Lung Function and Everyday Activity
- Cancer Drug May Double As an Arthritis Treatment
- IsoRay Medical's Cesium-131 Brachytherapy Treatment Combined With External Beam Radiation Therapy for the First Time at the Arnold Palmer Prostate Center at Eisenhower Medical Center
- AmpliMed Begins Patient Enrollment for Phase I Trial of Amplimexon(TM) Plus Docetaxel in Patients With Lung, Breast and Prostate Cancer
- Clinical Trial at Arkansas Cancer Research Center Demonstrates Breast Cancer Treatment Using RITA Medical Systems Radiofrequency Ablation Products Reduces Re-Excision Rates By 86%
 |
 |
User Comments (0)
RSS Feeds